Adage Capital Partners GP L.L.C. Has $32.01 Million Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Adage Capital Partners GP L.L.C. lifted its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 38.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,670,000 shares of the company's stock after acquiring an additional 465,000 shares during the period. Adage Capital Partners GP L.L.C. owned approximately 2.11% of Viridian Therapeutics worth $32,014,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. R Squared Ltd acquired a new stake in shares of Viridian Therapeutics in the fourth quarter worth $26,000. AlphaQuest LLC boosted its stake in Viridian Therapeutics by 119.0% during the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock worth $54,000 after buying an additional 1,519 shares in the last quarter. Summit Investment Advisors Inc. boosted its stake in Viridian Therapeutics by 24.7% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock worth $147,000 after buying an additional 1,516 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Viridian Therapeutics during the fourth quarter worth $164,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in Viridian Therapeutics during the fourth quarter worth $219,000.

Viridian Therapeutics Price Performance

Shares of NASDAQ VRDN traded up $0.06 during trading on Thursday, reaching $13.61. The company had a trading volume of 219,152 shares, compared to its average volume of 1,193,485. Viridian Therapeutics, Inc. has a 52 week low of $9.90 and a 52 week high of $27.20. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The business's 50 day moving average price is $14.05 and its 200-day moving average price is $18.07. The stock has a market cap of $1.11 billion, a PE ratio of -3.14 and a beta of 0.81.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, beating analysts' consensus estimates of ($1.05) by $0.24. The business had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. Analysts expect that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Analysts Set New Price Targets

VRDN has been the topic of a number of recent research reports. Needham & Company LLC reiterated a "buy" rating and set a $38.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. HC Wainwright reiterated a "buy" rating and set a $34.00 price target on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Viridian Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $35.70.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.